drugset / Trial / NCT05357612
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Phase 4
Recruiting
75 enrolled
Vanderbilt University Medical Center
ACADIA Pharmaceuticals Inc. · collab
NaSingle-groupOpen-labelBasic science
Summary
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Timeline
- Start
- 2023-01-23
- Primary completion
- 2027-06
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | — | — |